Drug Combination Details
| General Information of the Combination (ID: C14624) | |||||
|---|---|---|---|---|---|
| Name | Curcumin NP Info | + | TRAIL/Apo2L Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Ovarian cancer
[ICD-11: 2C73]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Cleavage | CASP8 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Cleavage | CASP9 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | A2780 | CVCL_0134 | Ovarian endometrioid adenocarcinoma | Homo sapiens | ||
| SK-OV-3 | CVCL_0532 | Ovarian serous cystadenocarcinoma | Homo sapiens | |||
| ES-2 | CVCL_3509 | Ovarian clear cell adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Combined curcumin and Apo2L/TRAIL treatment results in enhanced induction of apoptotic cell death. Curcumin and Apo2L/TRAIL together can activate both the extrinsic and intrinsic pathways of apoptosis. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Curcumin enhances Apo2L/TRAIL-induced apoptosis in chemoresistant ovarian cancer cells. Gynecol Oncol. 2007 Apr;105(1):104-12. | |||
